BMS-986020 sodium NEW
| Price | Get Latest Price |
| Package | 1removed |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-10-24 |
Product Details
| Product Name: BMS-986020 sodium | CAS No.: 1380650-53-2 |
| Supply Ability: 10g | Release date: 2025/10/24 |
Product Introduction
Bioactivity
| Name | BMS-986020 sodium |
| Description | BMS-986020 sodium (AM152 sodium) is a high-affinity LPA1 (Lysophosphatidic Acid Receptor 1) antagonist for investigating idiopathic pulmonary fibrosis, slowing the rate of decline in forced vital capacity (FVC) and pulmonary function. BMS-986020 inhibits bile acid and phospholipid transporters (BSEP, MRP4, MDR3), altering bile homeostasis. |
| In vitro | BMS-986020 sodium can inhibit the efflux transporters of bile acids in the liver, including BSEP (half-maximal inhibitory concentration IC₅₀ of 1.8μM), MRP3 (IC₅₀ of 22μM), and MRP4 (IC₅₀ of 6.2μM). At a concentration of 10μM, it suppresses the canalicular efflux of bile acids in Homo sapiens hepatocytes (inhibition rate of 68%). When the concentration reaches ≥10μM, BMS-986020 sodium impairs mitochondrial function in both Homo sapiens hepatocytes and cholangiocytes, including basal respiration, maximal respiration, adenosine triphosphate (ATP) production, and reserve capacity. Additionally, it inhibits phospholipid efflux in Homo sapiens hepatocytes (IC₅₀ for MDR3 is 7.5μM)[1]. |
| In vivo | BMS-986020 sodium (0.5, 2, 5, and 10 mg/kg, administered via gavage immediately or 3 hours after reperfusion) significantly reduced the cerebral infarction volume and neurological deficit scores induced by transient middle cerebral artery occlusion (tMCAO) in mice, with the most pronounced effects observed at doses of 5 and 10 mg/kg. Moreover, administration 3 hours after reperfusion provided equivalent protective efficacy[2]. |
| Storage | keep away from moisture,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 120.00 mg/mL (237.85 mM), Sonication is recommended. |
| Inhibitors Related | Radioprotectin-1 | DBIBB | ACT-1016-0707 | Ki16198 | Tetradecyl Phosphonate | LPA2 antagonist 2 | LPA1 receptor antagonist 1 | UCM-05194 | LX-1031 | 1-Oleoyl lysophosphatidic acid sodium | H2L5186303 | Ki16425 |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $47.00/1mg |
VIP6Y
|
TargetMol Chemicals Inc.
|
2025-11-10 | |
| $1141.00/500mg |
VIP2Y
|
TargetMol Chemicals Inc.
|
2025-10-27 | |
| $0.00/1KG |
VIP4Y
|
Wuhan Senwayer Century Chemical Co.,Ltd
|
2023-02-17 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, USA
INQUIRY